IN0V8 Posted - 1 week ago

$COR Opportunity Baird raises target price to $292 from $287 Leerink Partners raises target price to $287 from $275 Mizuho raises target price to $250 from $245

EARNMOAR Posted - 2 weeks ago

$COR Exhibit B

EARNMOAR Posted - 2 weeks ago

$COR Cencora Q4 '24 earnings call: https://www.youtube.com/watch?v=fmecgev1GlU

Benzinga Posted - 2 weeks ago

Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings https://www.benzinga.com/news/earnings/24/11/41780082/cencora-acquires-retina-care-practice-network-for-4-6-billion-boosts-dividend-on-better-than-expect $COR

OpenOutcrier Posted - 2 weeks ago

$COR (+2.6% pre) Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results https://ooc.bz/l/47020

DonCorleone77 Posted - 2 weeks ago

$COR Cencora sees FY25 CapEx ~$600M

DonCorleone77 Posted - 2 weeks ago

$COR Cencora sees FY25 adjusted free cash flow $2B-$3B

DonCorleone77 Posted - 2 weeks ago

$COR Cencora sees FY25 adjusted EPS $14.80-$15.10, consensus $14.71 Sees FY25 revenue growth of 7%-9%, consensus $311.2B.

DonCorleone77 Posted - 2 weeks ago

$COR Cencora reports Q4 adjusted EPS $3.34, consensus $3.22 Reports Q4 revenue $79.1B, consensus $77.65B. "Cencora took important steps forward in fiscal 2024 as we continued to evolve our global enterprise through the advancement of our pharmaceutical distribution capabilities and execute on our strategy," said Bob Mauch, President and Chief Executive Officer of Cencora. "This morning's announcement of our acquisition of Retina Consultants of America furthers our ability to build on our leadership in specialty and deliver on our strategic imperatives. The strength of our business, value of our strategy and unparalleled expertise of our team members continues to drive Cencora's performance and results." "As we move into fiscal 2025, we are leading with a customer-centric approach, embracing an enterprise-powered mindset and a focus on learning to ensure we remain a differentiated healthcare solutions provider, both now and into the future," Mauch continued. "Cencora is well positioned for continued growth and committed to long-term value creation for all our stakeholders as we continue to build on the critical role we play at the center of healthcare."

DonCorleone77 Posted - 2 weeks ago

$COR Cencora to acquire Retina Consultants of America for $4.6B in cash

gtrades31 Posted - 2 weeks ago

$COR Cencora (COR) Q4 2024 Earnings and Revenues Top Estimates: - EPS: $3.34 (est $3.22) Diff: +$0.12 (+4%) - Revenue: $79.05B (est $77.65) Diff: +$1.4B (+2%) #Cencora #Earnings

LiveSquawk Posted - 2 weeks ago

$COR | Cencora Q4 24 Earnings Adj EPS $2.34 (est $3.23) Sees 2025 Adj EPS $14.80 To $15.10 (est $14.79) Boosts Qtrly Div by 8%

TeresaTrades Posted - 2 weeks ago

Heavy options volume $COR $MQ $FYBR $SMG $EXAS

ChessGM Posted - 2 weeks ago

$COR Heads up alert! Only two days until Upcoming Earnings on Wednesday, 11/6/2024 Neutral (5.5) Cencora, Inc. (NYSE: $COR) has experienced a mixed sentiment reflected in its recent developments. The appointment of two seasoned executives, Francois Mandeville and Pawan Verma, to the enterprise leadership team is a strategic move aimed at enhancing its pharmaceutical-centric strategy and driving growth. Historically, this could indicate a focus on expansion and operational efficiency. However, there are concerns regarding insider selling, which may signal a lack of confidence among key stakeholders. Notably, the company's long-term performance has been commendable, with a reported 193% gain for investors over the past five years, suggesting robust growth potential. The current P/E ratio stands at an attractive 15.2, compared to the industry average of 18.5, indicating that the stock may still be undervalued. Moreover, the expected EPS growth of 12% year-over-year is promising, especially in the context of the pharmaceutical sector's overall growth trajectory. Revenue forecasts indicate a steady increase, aligning with the positive outlook from analysts who describe Cencora as a strong growth stock. The company's debt management also appears prudent, with key metrics suggesting that it is leveraging debt effectively to fuel growth without exposing itself to excessive risk. Looking ahead, Cencora is set to release its Fourth Quarter Fiscal 2024 earnings on November 6, 2024. Analysts generally expect the company to continue its trend of earnings surprises, with consensus estimates suggesting a potential beat on revenue and earnings per share. Historically, Cencora has demonstrated an ability to exceed earnings expectations, which could positively impact market sentiment and stock performance post-announcement. Investors will be keenly watching the upcoming report for insights into revenue growth, profitability, and guidance for the upcoming fiscal year, as these factors will be crucial in determining the stock's short-term trajectory. - Funds were net buyers of $COR during the previous reporting quarter. - Top 5 funds with large holdings in $COR: * Holocene Advisors LP $134MM. CGMRank: 85% * D. E. Shaw & Co $84MM. CGMRank: 85% * Balyasny Asset Management LLC $69MM. CGMRank: 68% * Adage Capital P $66MM. CGMRank: 87% * Farallon Capital Management LLC $55MM. CGMRank: 69% - Last 10 days performance: -3% - Last 30 days performance: 3% - Last 90 days performance: -8% Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.

insiderbuyingselling Posted - 10/23/24

$COR new insider selling: 21509 shares. http://insiderbuyingselling.com/?t=COR

WeeklyTrader Posted - 10/23/24

Who’s ready to cash in on $COR? RSI: 58.66% 50-day MA: $232.25 200-day MA: $231.32

WeeklyTrader Posted - 1 month ago

Feeling bullish? Grab a CALL on $COR at strike None before it’s too late! RSI: 45.59% 50-day MA: $232.68 200-day MA: $230.5

WeeklyTrader Posted - 1 month ago

Catch the wave with $COR! RSI: 39.06% 50-day MA: $233.13 200-day MA: $230.39

Bluechip03 Posted - 09/25/24

$COR Looking good for the upside entering long call side positions . I like this retest of 200 daily MA might take a month or so to push higher . Also retest of support from may

contangoz Posted - 2 months ago

$cor - paid 75m to hackers in march - bitcoin was used

drew8asante Posted - 2 months ago

CENCORA HACKERS WERE PAID $75 MILLION IN LARGEST KNOWN RANSOM $COR

IN0V8 Posted - 2 months ago

$COR Jefferies raises target price to $240 from $230

contangoz Posted - 2 months ago

$cor ms healthcare conference today

smartiss Posted - 2 months ago

$COR DONT support stock with BS about cv19. DOWNFALL for ALL of us

NewYorkCityMonkey Posted - 2 months ago

$WBA $COR up 2% 😅

Winning_calls Posted - 2 months ago

$COR 😘🫡🫡

Winning_calls Posted - 2 months ago

$COR more 🙏 🙏 🙏 🙏

Winning_calls Posted - 2 months ago

$COR pick me up @ $239.90 😉😉

scbeachbum Posted - 08/27/24

$WBA They have a lot of value in $COR they can sell and get cash. They sold over $1B there recently, they could free up another $4.5B there. That's over half their market cap. Selling Boots should yield another $8-9 Billion. The sum of their parts is worth a lot more than the current share price.

Dr_Stoxx Posted - 3 months ago

$COR -- anything health care is hot hot hot these days...the fastest growing sector of the economy...and this is a great play on the "picks and shovels" part of the industry (medical infrastructure). Strong @MarketSurge metrics support a move higher. #IBDPartner @InvestorsBusinessDaily